Industry News
Pharmaceutical Industry News
A patient in an open label…
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has passed away, the company and several hemophilia advocacy groups confirmed this week.
Neurocrine’s Ingrezza, approved…
Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to move the needle in a phase 3 trial in patients with dyskinesia due to cerebral palsy.
Drug pricing, layoffs, personnel…
Drug pricing, layoffs, personnel moves and other topics drove reader interest all year long. Here's a look at some of our top stories from the year.
Pharma giant AstraZeneca extended…
Pharma giant AstraZeneca extended its supply deal with Michigan-based medical radioisotope producer Niowave by 10 years, teeing up the delivery of Actinium-225 that has shown promise as a component in targeted cancer therapy.
CMS’ Innovation Center has…
CMS' Innovation Center has released two new drug pricing models that base rebates on international drug prices, which are significantly lower than what U.S. consumers pay for the same products.
Boehringer’s Jascayd can now crack…
Boehringer's Jascayd can now crack open the rare progressive pulmonary fibrosis disease market just two months after its initial market entry in idiopathic pulmonary fibrosis.
Slated for a Dec. 26 decision on…
Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the biotech its first U.S. nod since it was established in 1997. The agency has signed off
A six-month community awareness…
A six-month community awareness campaign has significantly increased colorectal cancer awareness in part of Nigeria, leading researchers to recommend expanding the model to the national level.
The acquisition will allow…
The acquisition will allow Shionogi to add a "strong rare disease commercial platform in the U.S. market," potentially supporting its planned launches in Fragile X syndrome, Jordan’s Syndrome and Pompe disease, the company said.
The approval for Lunsumio Velo…
The approval for Lunsumio Velo allows Roche to fill an administration convenience gap with AbbVie and Genmab's rival T-cell engager; all the while, the Swiss pharma has been touting the reduced burden of its fixed-duration
Incog BioPharma, a sterile…
Incog BioPharma, a sterile injectables CDMO, plans to shell out about $200 million to boost production capacity at its Fishers, Indiana, manufacturing site.
Samsung Bio’s U.S. subsidiary…
Samsung Bio’s U.S. subsidiary will pay $280 million to acquire GSK’s Human Genome Sciences and its two pharmaceutical manufacturing plants at a campus in Rockville, Maryland. The site, which will mark Samsung Bio’s first for
¿Por cuánto tiempo puedes tomar antidepresivos?
Estos medicamentos, creados para hacerte sentir bien, son difíciles de dejar sin la guía de un psiquiatra. Pedimos la opinión de varios expertos a este respecto.
Trump Announces Pricing Deals With Nine Drugmakers
The companies were the latest to agree to sell drugs to Medicaid and directly to consumers at discounted prices. President Trump said he would soon begin similar negotiations with health insurers.
F.D.A. Turmoil Keeps Spotlight on Its Commissioner
The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership of Dr. Marty Makary.
Updates on DTC advertising and DTP…
Updates on DTC advertising and DTP programs, as well as special reports, event coverage and, of course, news bulletins from the ever-evolving GLP-1 front all made the list of our most-read stories in 2025.
After a series of ownership…
After a series of ownership changes, Andexxa is slated to be pulled from the market in the coming days. The FDA said it "considers the risks of the product to outweigh its benefits."
The Elevidys-related manufacturing…
The Elevidys-related manufacturing shortfalls were described in one of two Form 483s tied to FDA inspections that came before Catalent's layoff spree at its Maryland gene therapy manufacturing business.
Sixteen months after luring former…
Sixteen months after luring former Roche dealmaker James Sabry, M.D., Ph.D., out of retirement and signaling a shift in its business development approach, BioMarin has announced the largest transaction in the company’s 28-year history.
Amgen, Boehringer Ingelheim,…
Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, GSK, Merck & Co., Novartis, Roche and Sanofi have agreed with the White House to reduce the prices of certain prescription medicines in exchange for pharmaceutical tariff